Novo Nordisk, Orbis Medicines Ink $1.4 Billion Deal for Oral Cardiometabolic Drugs

Orbis Medicines has entered into a drug discovery and licensing collaboration with pharmaceutical giant Novo Nordisk potentially worth up to $1.4 billion. The partnership, announced Thursday, aims to develop oral treatments for cardiometabolic diseases, targeting therapies that are currently available only as injections.

Deal Structure

The agreement's total value includes an upfront payment to Orbis, along with future development and commercial milestone payments. Orbis is also eligible to receive tiered royalties on net sales of any commercialized products that result from the collaboration.

As part of the deal, Novo Nordisk will also make a strategic equity investment in the privately-held Orbis Medicines. According to the announcement, the companies did not disclose the specific size of the investment or the breakdown of the potential $1.4 billion in payments.

Scientific Collaboration

The partnership will leverage Orbis's proprietary, AI-enabled platform, known as nGen, to discover and develop new drug candidates. The focus will be on identifying macrocycles, a class of molecules with properties that make them suitable for oral administration, a significant challenge for many biologic drugs.

Ad

The goal is to transform injectable therapies for multiple targets within the cardiometabolic space into more convenient oral medications. This could improve patient adherence and expand access to treatments for chronic conditions like diabetes and obesity.

Market Context

This collaboration underscores a major strategic push within the pharmaceutical industry to develop oral alternatives to highly successful injectable drugs. For Novo Nordisk, a market leader in injectable metabolic therapies, this deal represents a key investment in next-generation treatment modalities.

For Orbis Medicines, the partnership provides significant non-dilutive funding and a powerful validation of its technology platform from an established industry leader. The agreement allows Orbis to apply its AI-driven approach to a high-value therapeutic area with a large global patient population.